Table 4.

The effect of synthesized thiosemicarbazones 2a–k and 3a–j on the viability of Hep3B, Hela, A549, and MCF-7 cells after 48 h of incubation.

Comp. No.	Conc.	Hep3B	Hela	A549	MCF-7
2a	30 µM	69.07 ± 1.37	71.58 ± 1.49	75.40 ± 1.50	58.80 ± 1.23
	100 µM	64.47 ± 0.86	60.07 ± 0.97	70.38 ± 0.94	49.35 ± 0.79
2b	30 µM	76.33 ± 1.79	55.29 ± 1.10	83.32 ± 1.96	45.42 ± 0.91
	100 µM	70.72 ± 0.46	53.8 ± 1.41	77.2 ± 0.50	43.31 ± 2.63
2c	30 µM	68.6 ± 2.74	72.09 ± 2.30	76.36 ± 1.82	59.22 ± 1.89
	100 µM	59.84 ± 2.20	59.67 ± 1.43	65.32 ± 2.40	49.02 ± 1.18
2d	30 µM	19.34 ± 2.54	61.12 ± 1.91	21.11 ± 2.78	50.21 ± 1.57
	100 µM	16.82 ± 1.60	24.55 ± 1.85	18.37 ± 1.75	20.17 ± 1.52
2e	30 µM	67.73 ± 1.34	72.77 ± 2.42	73.94 ± 1.46	59.79 ± 1.99
	100 µM	68.2 ± 0.63	61.01 ± 1.16	74.45 ± 0.69	50.12 ± 0.95
2f	30 µM	63.5 ± 1.47	69.84 ± 1.85	69.32 ± 1.61	57.38 ± 1.52
	100 µM	54.53 ± 1.19	57.2 ± 2.90	59.53 ± 1.30	47.00 ± 2.38
2g	30 µM	76.83 ± 2.31	71.65 ± 2.01	83.87 ± 2.52	42.50 ± 2.35
	100 µM	70.25 ± 0.41	47.9 ± 2.03	76.69 ± 0.44	39.35 ± 1.67
2h	30 µM	23.71 ± 0.88	44.42 ± 2.35	25.88 ± 0.96	36.50 ± 1.93
	100 µM	21.86 ± 0.20	34.76 ± 1.36	23.86 ± 0.22	28.55 ± 1.12
2i	30 µM	78.88 ± 2.63	64.37 ± 1.47	86.11 ± 2.88	52.89 ± 1.21
	100 µM	76.06 ± 0.27	61.4 ± 0.17	83.03 ± 0.29	50.45 ± 0.14
2j	30 µM	65.01 ± 2.17	46.16 ± 0.38	70.97 ± 2.37	37.92 ± 0.31
	100 µM	62.83 ± 2.23	40.66 ± 1.04	68.59 ± 2.43	33.40 ± 0.86
2k	30 µM	67.46 ± 1.69	69.88 ± 2.12	73.64 ± 1.84	57.41 ± 1.74
	100 µM	46.78 ± 0.21	55.18 ± 2.92	51.06 ± 0.23	45.33 ± 2.40
3a	30 µM	72.06 ± 1.92	74.40 ± 1.07	78.67 ± 2.09	61.12 ± 0.88
	100 µM	67.93 ± 1.11	69.77 ± 0.35	74.16 ± 1.22	57.32 ± 0.29
3b	30 µM	75.15 ± 0.36	70.17 ± 1.90	82.04 ± 0.40	57.64 ± 1.56
	100 µM	71.76 ± 0.48	68.65 ± 2.51	78.34 ± 0.52	56.40 ± 2.06
3c	30 µM	85.76 ± 2.42	81.90 ± 2.11	93.62 ± 2.64	67.28 ± 1.74
	100 µM	68.37 ± 1.58	64.27 ± 2.47	74.63 ± 1.73	52.80 ± 2.03
3d	30 µM	80.15 ± 1.68	81.46 ± 1.60	87.5 ± 1.83	66.92 ± 1.31
	100 µM	72.57 ± 1.83	73.28 ± 2.50	79.22 ± 2.00	60.20 ± 2.05
3e	30 µM	67.02 ± 1.37	80.59 ± 1.39	73.17 ± 1.49	66.21 ± 1.14
	100 µM	53.79 ± 0.71	77.66 ± 0.29	58.72 ± 0.77	63.80 ± 0.24
3f	30 µM	72.26 ± 1.01	77.05 ± 2.19	78.89 ± 1.11	63.30 ± 1.80
	100 µM	65.95 ± 0.25	67.78 ± 1.64	71.99 ± 0.28	55.68 ± 1.35
3g	30 µM	80.42 ± 1.16	62.38 ± 0.71	87.79 ± 1.27	51.25 ± 0.58
	100 µM	70.65 ± 1.77	51.23 ± 0.49	77.13 ± 1.94	42.09 ± 0.40
3h	30 µM	75.08 ± 1.11	81.90 ± 1.04	81.96 ± 1.21	67.28 ± 0.85
	100 µM	67.16 ± 2.57	75.92 ± 1.60	73.31 ± 2.81	62.37 ± 1.31
3i	30 µM	78.34 ± 0.71	77.12 ± 2.03	85.52 ± 0.77	63.36 ± 1.67
	100 µM	74.04 ± 0.61	56.81 ± 1.81	80.83 ± 0.67	46.67 ± 1.49
3j	30 µM	69.54 ± 2.39	87.18 ± 1.91	75.92 ± 2.61	71.62 ± 1.57
	100 µM	61.25 ± 2.24	74.51 ± 2.17	66.86 ± 2.45	61.21 ± 1.78
CPT *	0.3 μM	69.56 ± 1.27	57.06 ± 1.35	67.68 ± 1.88	56.68 ± 0.68
	14.4 μM	37.65 ± 1.21	18.61 ± 0.56	26.74 ± 2.16	28.89 ± 1.07

* Camptothecin. Data is presented as percentage of the cell viability ± SD.